CTOs on the Move

Glen Research Corporation

www.glenres.com

 
Glen Research Corporation is a Sterling, VA-based company in the Healthcare, Pharmaceuticals, and Biotech sector.
  • Number of Employees: 25-100
  • Annual Revenue: $10-50 Million
  • www.glenres.com
  • 22825 Davis Dr
    Sterling, VA USA 20164
  • Phone: 703.437.6191

Executives

Name Title Contact Details

Similar Companies

DotLab

DotLab is shaping the future of women`s healthcare technology by developing the first test for endometriosis, affecting 1 in 10 women worldwide.

Bavarian Nordic

Bavarian Nordic is a fully integrated biotechnology company focused on the development, manufacture and commercialization of life-saving vaccines.

Whole Biome

Whole Biome`s mission is to be the trusted brand in bringing the public improved health solutions through microbiome interventions. We are developing microbiome diagnostics and interventions using our proprietary discovery platform.

Ionpath

Ionpath delivers high definition spatial proteomics, revolutionizing tissue imaging and analysis to accelerate discovery and improve human health. Ionpath`s MIBI™ (multiplexed ion beam imaging) Platform breaks through the limitations of traditional IHC, enabling deep understanding of the tissue microenvironment with highly multiplexed quantitative single-cell analysis.

Galena Biopharma

Galena Biopharma, Inc. is a biopharmaceutical company committed to the development and commercialization of targeted oncology therapeutics that address major unmet medical needs. Galena’s development portfolio is focused primarily on addressing the rapidly growing patient populations of cancer survivors by harnessing the power of the immune system to prevent cancer recurrence. The Company’s pipeline consists of multiple mid- to late-stage clinical assets, including novel cancer immunotherapy programs led by NeuVax™ (nelipepimut-S) and GALE-301. NeuVax is currently in a pivotal, Phase 3 clinical trial with several concurrent Phase 2 trials ongoing both as a single agent and in combination with other therapies. GALE-301 is in a Phase 2a clinical trial in ovarian and endometrial cancers and in a Phase 1b given sequentially with GALE-302.